SCHEMBL3339408

SCHEMBL3339408

COC(=O)c1[nH]c(Cl)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.40
CYP1A2 P05177 1/20 0.39
RAF1 P04049 1/20 0.39
GAA P10253 4/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
PADI4 Q9UM07 1/20 0.38
NR4A2 P43354 1/20 0.38
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
RHEB Q15382 1/20 0.37
ABL1 P00519 1/20 0.37
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20568972 0.82 GAA (0.45) MAPK14CYP1A2RAF1GAAALDH1A1
SCHEMBL5863570 0.79 CYP1A2 (0.49) CYP1A2GAAALDH1A1KDM4EMAPT
SCHEMBL3029318 0.79 NGFR (0.42) MAPK14CYP1A2ALDH1A1KDM4EHPGD
SCHEMBL3035325 0.79 CYP1A2 (0.40) MAPK14CYP1A2RAF1GAAALDH1A1
SCHEMBL3031984 0.79 CYP1A2 (0.40) MAPK14CYP1A2RAF1GAAALDH1A1
SCHEMBL3017649 0.78 MAPK1 (0.39) MAPK14CYP1A2RAF1GAAALDH1A1
SCHEMBL3024994 0.78 GAA (0.41) MAPK14RAF1GAAALDH1A1HTT
SCHEMBL3027631 0.77 GAA (0.41) MAPK14RAF1GAAALDH1A1KDM4E
SCHEMBL15051392 0.76 GAA (0.46) GAAKDM4EHTTNR4A2MAPT
SCHEMBL20568522 0.75 TDP1 (0.38) MAPK14GAAALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793879-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096637-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096637-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165483-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165483-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165483-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-06-17 US disclosed
EP-2057161-A2 4-OXO-4,5-DIHYDROPYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-05-13 EP disclosed
WO-2008017883-A2 4-OXO-4,5-DIHYDROPYRROLO[1,2-A] QUINOXALINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165483-A1 HETEROARYLS AND USES THEREOF PIK3R5, PIK3R4, PIK3C2B MAPK14 1291/4885CYP1A2 2026/4885RAF1 1704/4885
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) PARP1, PARP2, PARP4 MAPK14 1782/4885CYP1A2 1996/4885RAF1 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.